Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2011

View Archived Issues

New clinical data presented on brentuximab vedotin

Selective ROCK-2 inhibitors presented by University of Michigan

Targeted secretion inhibitors SXN-101000 and SXN-101742 inhibit growth hormone secretion in vivo

Aliskiren shows efficacy in children with hypertension

New GPR119 receptor agonists claimed by Pfizer

Researchers at GSK present new antimalarial agents

Novel muscarinic acetylcholine M1 receptor modulators disclosed

Merck KGaA presents new HSP 90 inhibitors

Cubist Pharmaceuticals reports phase II data on CXA-201 and CB-183315

FDA committee recommends approval of VEGF Trap-Eye for wet AMD

Photocure begins enrolling women with CIN due to HPV infection in phase II Cevira trial

Yeast-based vaccine GI-6207 is safe in phase I trial in metastatic cancer expressing CEA

Fostamatinib disodium improves quality of life in subjects with active rheumatoid arthritis

Pentraxin-related protein PTX3 described as novel biomarker in advanced pancreatic cancer

Takeda begins phase III study of TAK-816 vaccine in Japan

Sunshine Biopharma and the Jewish General Hospital to collaborate on Adva-27a

National Eye Institute awards grant to Cedars-Sinai to develop stem cell therapies

LMS-611 obtains European orphan drug status in cystic fibrosis

Azellon to conduct phase I stem cell trial in the U.K. for meniscal tears

Wilex provides update on the Redectane approval process

Theratechnologies seeks approval for Egrifta in Canada

NovaBay and Alcon terminate Aganocides collaboration and license agreement

GTx begins phase IIb trial comparing Capesaris to Lupron Depot in advanced prostate cancer

FDA approves new 6-month formulation of Lupron Depot for advanced prostate cancer

Chelsea Therapeutics reports encouraging results from QTc interval study of Northera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...